Search Results - "Bélanger, B"

Natural regulatory (CD4 +CD25 +FOXP +) T cells control the production of pro-inflammatory cytokines during Plasmodium chabaudi adami infection and do not contribute to immune evasion by Cambos, M., Bélanger, B., Jacques, A., Roulet, A., Scorza, T.

“…Different functions have been attributed to natural regulatory CD4 +CD25 +FOXP + (Treg) cells during malaria infection. Herein, we assessed the role for Treg…”
Get full text

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells by MALCOLM, B. A, LIU, R, INGRAVALLO, P, JIANG, C, KONG, R, LU, J, PICHARDO, J, PRONGAY, A, SKELTON, A, TONG, X, VENKATRAMAN, S, XIA, E, LAHSER, F, GIRIJAVALLABHAN, V, NJOROGE, F. G, AGRAWAL, S, BELANGER, B, BUTKIEWICZ, N, CHASE, R, GHEYAS, F, HART, A, HESK, D

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer by Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, J‐S, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I, Ma, WW

“…Nanoliposomal irinotecan (nal‐IRI) is a liposomal formulation of irinotecan with a longer half‐life (t1/2), higher plasma total irinotecan (tIRI), and lower…”
Get full text

Effectiveness and Feasibility of Healthy Menu Changes for Non-Trainee Military Dining Facilities by Belanger, B, Kwon, J

Get full text

Factors Influencing Food Selection and Nutrient Intakes of Non-Trainee Army Dining Facility Patrons by Kwon, J, Belanger, B

Get full text

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer by Wainberg, Z., Boland, P., Lieu, C., Dayyani, F., Macarulla, T., Zhang, B., Belanger, B., Moore, Y., Wang, T., Maxwell, F., Dean, A.

Get full text

The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) by Chen, L.-T., Macarulla, T.M., Belanger, B., Mirakhur, B., de Jong, F.A., Siveke, J.

Get full text

North American Hydroclimate During Past Warms States: A Proxy Compilation‐Model Comparison for the Last Interglacial and the Mid‐Holocene by Wet, C. B., Ibarra, D. E., Belanger, B. K., Oster, J. L.

“…During the mid‐Holocene (MH: ∼6,000 years Before Present) and Last Interglacial LIG (LIG: ∼129,000–116,000 years Before Present) differences in the seasonal…”
Get full text

Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 by Chen, L.-T., Macarulla, T.M., Blanc, J., Mirakhur, B., de Jong, F.A., Belanger, B., Bekaii-Saab, T., Siveke, J.

Get full text

TU‐B‐ValA‐01: Digital Fluoroscopic Imaging: Acquisition, Processing and Display by Belanger, B

“…The modern digital fluoroscopic imaging system has evolved to levels of complexity and automation that, when properly applied, can provide enhanced clinical…”
Get full text

2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies by Ma, W.W, Chung, I, Lang, I, Csõszi, T, Wenczl, M.W, Cubillo, A, Chen, J, Wong, M, Park, J.O, Kim, J.S, Rau, K.M, Melichar, B, Gallego, J, Smakal, M, Kim, J, Belanger, B, Bayever, E, Adiwijaya, B

Get full text

Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core by Yu, Tao, Tagat, Jayaram R, Kerekes, Angela D, Doll, Ronald J, Zhang, Yonglian, Xiao, Yushi, Esposite, Sara, Belanger, David B, Curran, Patrick J, Mandal, Amit K, Siddiqui, M. Arshad, Shih, Neng-Yang, Basso, Andrea D, Liu, Ming, Gray, Kimberly, Tevar, Seema, Jones, Jennifer, Lee, Suining, Liang, Lianzhu, Ponery, Samad, Smith, Elizabeth B, Hruza, Alan, Voigt, Johannes, Ramanathan, Lata, Prosise, Winifred, Hu, Mengwei

“…The imidazo-[1,2-a]-pyrazine (1) is a dual inhibitor of Aurora kinases A and B with modest cell potency (IC50 = 250 nM) and low solubility (5 μM). Lead…”
Get full text

Thermal promotion of the cobalt catalyzed intramolecular Pauson-Khand reaction — An alternative experimental protocol for cyclopentenone synthesis by Belanger, David B., O'Mahony, Donogh J.R., Livinghouse, Tom

“…Heat alone has been found sufficient to promote intramolecular Pauson-Khand cyclizations catalyzed by high purity Co 2(CO) 8. The existence of a very narrow…”
Get full text

In vivo manipulation of human gut Bacteroides fitness by abiotic oligosaccharides by Wesener, Darryl A, Beller, Zachary W, Hill, Megan F, Yuan, Han, Belanger, David B, Frankfater, Cheryl, Terrapon, Nicolas, Henrissat, Bernard, Rodionov, Dmitry A, Leyn, Semen A, Osterman, Andrei, van Hylckama Vlieg, Johan E T, Gordon, Jeffrey I

“…Synthetic glycans (SGs) containing glycosidic linkages and structures not identified in nature offer a means for deliberately altering microbial community…”
Get full text

Abstract No. 84: UFE: Methods of Dose Reduction and Pain Management in an Out-Patient Environment: An Initial Study by Niedzwiecki, G.A, Bugman, S, Ravindar, P, Belanger, B

Get full text

966 IDX184, A LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR: RESULTS OF A FIRST-IN-MAN SAFETY AND PHARMACOKINETIC STUDY by Zhou, X.-J, Pietropaolo, K, Sullivan-Bolyai, J, Kuca, B, Liu, W, Xu, L, Belanger, B, Khan, S, Mayers, D

Get full text

Machine Learning ADME Models in Practice: Four Guidelines from a Successful Lead Optimization Case Study by Rich, Alexander S., Chan, Yvonne H., Birnbaum, Benjamin, Haider, Kamran, Haimson, Joshua, Hale, Michael, Han, Yongxin, Hickman, William, Hoeflich, Klaus P., Ortwine, Daniel, Özen, Ayşegül, Belanger, David B.

“…Optimization of the ADME properties and pharmacokinetic (PK) profile of compounds is one of the critical activities in any medicinal chemistry campaign to…”
Get full text

Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway by Karki, Rajeshri G, Powers, James, Mainolfi, Nello, Anderson, Karen, Belanger, David B, Liu, Donglei, Ji, Nan, Jendza, Keith, Gelin, Christine F, Mac Sweeney, Aengus, Solovay, Catherine, Delgado, Omar, Crowley, Maura, Liao, Sha-Mei, Argikar, Upendra A, Flohr, Stefanie, La Bonte, Laura R, Lorthiois, Edwige L, Vulpetti, Anna, Brown, Ann, Long, Debby, Prentiss, Melissa, Gradoux, Nathalie, de Erkenez, Andrea, Cumin, Frederic, Adams, Christopher, Jaffee, Bruce, Mogi, Muneto

“…Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the…”
Get full text

Manipulating glucocorticoids in wild animals: basic and applied perspectives by Sopinka, Natalie M., Patterson, Lucy D., Redfern, Julia C., Pleizier, Naomi K., Belanger, Cassia B., Midwood, Jon D., Crossin, Glenn T., Cooke, Steven J.

“…Experimental elevations of glucocorticoids are used to understand how chronic exposure to stressors affects vertebrate performance. A variety of methods exist…”
Get full text

1534P Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan by Abushahin, L., Cockrum, P., Surinach, A., Belanger, B.

Get full text